State your position on sponsored CME

Should the era of pharma-sponsored CME draw to a close? Or is industry-funded medical education an essential cog in the healthcare machine? Weigh in with your opinion at the Pharma Marketing Blog. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.